Shares of Biocon Ltd. surged by 3% today following its subsidiary Biocon Biologics Ltd.’s (BBL) announcement of a major regulatory milestone. The Pharmaceuticals and Medical Devices Agency (PMDA) of Japan granted approval for the commercialization of Ustekinumab BS, a biosimilar version of Johnson & Johnson’s Stelara®, in Japan.
As of 9:20 am the shares were trading 3% higher at ₹368.80 on NSE.
Key Highlights:
- Regulatory Approval: Biocon Biologics received approval to market Ustekinumab BS in Japan, targeting chronic autoimmune conditions like Psoriasis Vulgaris and Psoriatic Arthritis.
- Commercial Partnership: The biosimilar will be launched in collaboration with Yoshindo Inc., Biocon Biologics’ exclusive partner in the Japanese market.
- Global Collaboration: The approval follows Biocon Biologics’ licensing agreement with Janssen Biotech Inc. and Johnson & Johnson in August 2024, which resolved IP disputes and enabled global commercialization of Ustekinumab biosimilars.
- Therapeutic Potential: Ustekinumab is a monoclonal antibody targeting IL-12 and IL-23, crucial inflammatory drivers in autoimmune diseases, making it a cornerstone therapy for these conditions.
Biocon Share Price history
| Day | Open | Close | Change % |
|---|---|---|---|
|
Mon, Jan 6 2025
|
₹369.45
|
₹358.10
|
-3.02%
|
|
Fri, Jan 3 2025
|
₹376.95
|
₹369.25
|
-1.07%
|
|
Thu, Jan 2 2025
|
₹368.80
|
₹373.25
|
|
|
Wed, Jan 1 2025
|
₹366.90
|
₹368.80
|
|
|
Tue, Dec 31 2024
|
₹365.75
|
₹365.35
|
-0.64%
|
|
Mon, Dec 30 2024
|
₹355.00
|
₹367.70
|
|
|
Fri, Dec 27 2024
|
₹346.75
|
₹352.55
|
|
|
Thu, Dec 26 2024
|
₹342.75
|
₹346.45
|
|
